Moreover, the combination drug doses tested did not result in further reductions of AngII-induced AAAs than did administration of valsartan alone, and for some parameters (maximal AAA external diameters), significant reductions by valsartan (0.5 mg/kg per day) were no longer evident when combined with sacubitril (Fig. 3, A and B). The gene discussed is AGT; the disease is achalasia-alacrima syndrome.